Vaccines: From Empirical Development to Rational Design

PLoS Pathogens

Volumn 8, Issue 11, 2012, Pages

  Rueckert, Christine ^a   Guzmán, Carlos A ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIGEN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; VACCINE; VIRUS LIKE PARTICLE VACCINE; VIRUS VECTOR;

ANTIGEN PRESENTING CELL; COMPUTER MODEL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DESIGN; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFECTION; NONHUMAN; REVIEW; T LYMPHOCYTE; VACCINATION; VACCINE PRODUCTION;

ANIMALS; ANTIGENS; HUMANS; INFECTION CONTROL; VACCINATION; VACCINES;

EID: 84870816984     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003001     Document Type: Review

References (108)

1. Theiler M, Smith HH, (1937) The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 65: 787-800.
2. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K, (1981) Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59: 895-900.
3. Sette A, Rappuoli R, (2010) Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33: 530-541.
4. Bagnoli F, Baudner B, Mishra RP, Bartolini E, Fiaschi L, et al. (2011) Designing the next generation of vaccines for global public health. OMICS 15: 545-566.
5. Poland GA, Kennedy RB, Ovsyannikova IG, (2011) Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery? PLoS Pathog 7: e1002344 doi:10.1371/journal.ppat.1002344.
6. Kennedy RB, Poland GA, (2011) The top five "game changers" in vaccinology: toward rational and directed vaccine development. OMICS 15: 533-537.
7. Ponomarenko JV, Regenmortel MHVv (2009) B-cell epitope prediction. In: Gu J, Bourne PE, editors. Structural bioinformatics, second ed. John Wiley & Sons, Inc.
8. Blythe MJ, Flower DR, (2005) Benchmarking B cell epitope prediction: underperformance of existing methods. Protein Sci 14: 246-248.
9. El-Manzalawy Y, Dobbs D, Honavar V, (2008) Predicting linear B-cell epitopes using string kernels. J Mol Recognit 21: 243-255.
10. El-Manzalawy Y, Dobbs D, Honovar V (2008) BCPREDS: B-cell epitope prediction server. Artificial Intelligence Research Laboratory, Department of Computer Science, Iowa State University of Science and Technology. Available: http://ailab.cs.iastate.edu/bcpreds/. Accessed August 2012.
11. Wee LJ, Simarmata D, Kam YW, Ng LF, Tong JC, (2010) SVM-based prediction of linear B-cell epitopes using Bayes Feature Extraction. BMC Genomics 11 (Suppl 4):: S21.
12. Wee LJ, Simarmata D, Kam YW, Ng HL, Tong JC (2010) BayesB: server for SVM prediction of linear B-cell epitopes using Bayes Feature Extraction. Available: http://www.immunopred.org/bayesb/index.html. Accessed August 2012.
13. Moreau V, Fleury C, Piquer D, Nguyen C, Novali N, et al. (2008) PEPOP: computational design of immunogenic peptides. BMC Bioinformatics 9: 71.
14. Moreau V, Fleury C, Piquer D, Nguyen C, Novali N, et al. (2008) PEPOP. Available: http://pepop.sysdiag.cnrs.fr/PEPOP/. Accessed August 2012.
15. Lundegaard C, Lund O, Buus S, Nielsen M, (2010) Major histocompatibility complex class I binding predictions as a tool in epitope discovery. Immunology 130: 309-318.
16. Li Pira G, Ivaldi F, Moretti P, Manca F, (2010) High throughput T epitope mapping and vaccine development. J Biomed Biotechnol 2010: 325720.
17. Wang P, Sidney J, Kim Y, Sette A, Lund O, et al. (2010) Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics 11: 568.
18. Tung CW, Ziehm M, Kamper A, Kohlbacher O, Ho SY, (2011) POPISK: T-cell reactivity prediction using support vector machines and string kernels. BMC Bioinformatics 12: 446.
19. Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof I, et al. (2010) The immune epitope database 2.0. Nucleic Acids Res 38: D854-D862.
20. Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof I, et al. (2009) Immune Epitope Database and Analysis Resource. Available: http://www.immuneepitope.org/. Accessed August 2012.
21. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S, (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213-219.
22. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) Available: http://www.syfpeithi.de/. SYFPEITHI: a database of MHC ligands and peptide motifs. Accessed August 2012.
23. Toussaint NC, Kohlbacher O, (2009) OptiTope-a web server for the selection of an optimal set of peptides for epitope-based vaccines. Nucleic Acids Res 37: W617-W622.
24. Toussaint NC, Kohlbacher O (2009) Available: http://www.epitoolkit.org/optitope. Accessed August 2012.
25. Karosiene E, Lundegaard C, Lund O, Nielsen M, (2012) NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. Immunogenetics 64: 177-186.
26. Karosiene E, Lundegaard C, Lund O, Nielsen HM (2012) NetMHCcons 1.0 server. Available: http://www.cbs.dtu.dk/services/NetMHCcons/. Accessed August 2012.
27. Kaur K, Sullivan M, Wilson PC, (2011) Targeting B cell responses in universal influenza vaccine design. Trends Immunol 32: 524-531.
28. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, et al. (2007) Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13: 100-106.
29. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, et al. (2010) Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16: 319-323.
30. Santra S, Liao HX, Zhang R, Muldoon M, Watson S, et al. (2010) Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 16: 324-328.
31. Clo E, Kracun SK, Nudelman AS, Jensen KJ, Liljeqvist JA, et al. (2012) Characterization of the viral O-glycopeptidome: a novel tool of relevance for vaccine design and serodiagnosis. J Virol 86: 6268-6278.
32. Lazaro E, Kadie C, Stamegna P, Zhang SC, Gourdain P, et al. (2011) Variable HIV peptide stability in human cytosol is critical to epitope presentation and immune escape. J Clin Invest 121: 2480-2492.
33. Dimitrov JD, Kazatchkine MD, Kaveri SV, Lacroix-Desmazes S, (2011) "Rational vaccine design" for HIV should take into account the adaptive potential of polyreactive antibodies. PLoS Pathog 7: e1002095 doi:10.1371/journal.ppat.1002095.
34. Wang Y, Keck ZY, Foung SK, (2011) Neutralizing antibody response to hepatitis C virus. Viruses 3: 2127-2145.
35. Haynes BF, Kelsoe G, Harrison SC, Kepler TB, (2012) B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 30: 423-433.
36. Ofek G, Guenaga FJ, Schief WR, Skinner J, Baker D, et al. (2010) Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A 107: 17880-17887.
37. Nuccitelli A, Cozzi R, Gourlay LJ, Donnarumma D, Necchi F, et al. (2011) Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proc Natl Acad Sci U S A 108: 10278-10283.
38. Scarselli M, Arico B, Brunelli B, Savino S, Di Marcello F, et al. (2011) Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med 3: 91ra62.
39. Adkins I, Holubova J, Kosova M, Sadilkova L, (2012) Bacteria and their toxins tamed for immunotherapy. Curr Pharm Biotechnol 13: 1446-1473.
40. Montomoli E, Piccirella S, Khadang B, Mennitto E, Camerini R, et al. (2011) Current adjuvants and new perspectives in vaccine formulation. Expert Rev Vaccines 10: 1053-1061.
41. Harandi AM, Davies G, Olesen OF, (2009) Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Rev Vaccines 8: 293-298.
42. Harandi AM, Medaglini D, Shattock RJ, (2010) Vaccine adjuvants: a priority for vaccine research. Vaccine 28: 2363-2366.
43. Harandi AM, Medaglini D, (2010) Mucosal adjuvants. Curr HIV Res 8: 330-335.
44. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, et al. (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350: 896-903.
45. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, et al. (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745.
46. Libanova R, Becker PD, Guzman CA, (2012) Cyclic di-nucleotides: new era for small molecules as adjuvants. Microb Biotechnol 5: 168-176.
47. Thompson AL, Staats HF, (2011) Cytokines: the future of intranasal vaccine adjuvants. Clin Dev Immunol 2011: 289597.
48. Asanuma H, Zamri NB, Sekine S, Fukuyama Y, Tokuhara D, et al. (2012) A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging. Vaccine 30: 803-812.
49. Chiang CY, Huang MH, Hsieh CH, Chen MY, Liu HH, et al. (2012) Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses. PLoS Negl Trop Dis 6: e1645 doi:10.1371/journal.pntd.0001645.
50. Krieg AM, (2012) CpG still rocks! Update on an accidental drug. Nucleic Acid Ther 22: 77-89.
51. Shafique M, Wilschut J, de Haan A, (2012) Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands. Vaccine 30: 597-606.
52. Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM, (2011) CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 10: 499-511.
53. Akira S, (2011) Innate immunity and adjuvants. Philos Trans R Soc Lond B Biol Sci 366: 2748-2755.
54. Kwissa M, Kasturi SP, Pulendran B, (2007) The science of adjuvants. Expert Rev Vaccines 6: 673-684.
55. Pulendran B, Ahmed R, (2011) Immunological mechanisms of vaccination. Nat Immunol 12: 509-517.
56. Brave A, Ljungberg K, Wahren B, Liu MA, (2007) Vaccine delivery methods using viral vectors. Mol Pharm 4: 18-32.
57. Liu MA, (2010) Immunologic basis of vaccine vectors. Immunity 33: 504-515.
58. Hu B, Tai A, Wang P, (2011) Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev 239: 45-61.
59. Buffa V, Negri DR, Leone P, Bona R, Borghi M, et al. (2006) A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice. J Gen Virol 87: 1625-1634.
60. Buffa V, Negri DR, Leone P, Borghi M, Bona R, et al. (2006) Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo. Viral Immunol 19: 690-701.
61. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, et al. (2012) Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 122: 359-367.
62. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
63. Bassett JD, Swift SL, Bramson JL, (2011) Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors. Expert Rev Vaccines 10: 1307-1319.
64. Dudareva M, Andrews L, Gilbert SC, Bejon P, Marsh K, et al. (2009) Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 27: 3501-3504.
65. Tatsis N, Blejer A, Lasaro MO, Hensley SE, Cun A, et al. (2007) A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol Ther 15: 608-617.
66. von Bubnoff A, (2012) Adenovirus vectors: promise and possible pitfalls. IAVI Rep 16: 4-7.
67. Hansen SG, Powers CJ, Richards R, Ventura AB, Ford JC, et al. (2010) Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328: 102-106.
68. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, et al. (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473: 523-527.
69. Lousberg EL, Diener KR, Brown MP, Hayball JD, (2011) Innate immune recognition of poxviral vaccine vectors. Expert Rev Vaccines 10: 1435-1449.
70. Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV, (2011) Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 23: 377-382.
71. Link C, Ebensen T, Standner L, Dejosez M, Reinhard E, et al. (2006) An SopB-mediated immune escape mechanism of Salmonella enterica can be subverted to optimize the performance of live attenuated vaccine carrier strains. Microbes Infect 8: 2262-2269.
72. Juarez-Rodriguez MD, Arteaga-Cortes LT, Kader R, Curtiss R 3rd, Clark-Curtiss JE, (2012) Live attenuated Salmonella vaccines against Mycobacterium tuberculosis with antigen delivery via the type III secretion system. Infect Immun 80: 798-814.
73. Juarez-Rodriguez MD, Yang J, Kader R, Alamuri P, Curtiss R 3rd, et al. (2012) Live attenuated Salmonella vaccines displaying regulated delayed lysis and delayed antigen synthesis to confer protection against Mycobacterium tuberculosis. Infect Immun 80: 815-831.
74. Galen JE, Simon R, Ernst RK, (2011) Salmonella expressing detoxified lipopolysaccharide is immunogenic and protective both as an attenuated vaccine and for delivery of foreign antigens. Expert Rev Vaccines 10: 1679-1682.
75. Johnson PV, Blair BM, Zeller S, Kotton CN, Hohmann EL, (2011) Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers. Microbiol Immunol 55: 304-317.
76. Caminschi I, Shortman K, (2012) Boosting antibody responses by targeting antigens to dendritic cells. Trends Immunol 33: 71-77.
77. Flynn BJ, Kastenmuller K, Wille-Reece U, Tomaras GD, Alam M, et al. (2011) Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A 108: 7131-7136.
78. Giles BM, Crevar CJ, Carter DM, Bissel SJ, Schultz-Cherry S, et al. (2012) A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis 205: 1562-1570.
79. Ramirez K, Wahid R, Richardson C, Bargatze RF, El-Kamary SS, et al. (2012) Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers. Clin Immunol 144: 98-108.
80. Ruiss R, Jochum S, Wanner G, Reisbach G, Hammerschmidt W, et al. (2011) A virus-like particle-based Epstein-Barr virus vaccine. J Virol 85: 13105-13113.
81. Pastori C, Tudor D, Diomede L, Drillet AS, Jegerlehner A, et al. (2012) Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41. Virology 431: 1-11.
82. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, et al. (2011) Clinical applications of DNA vaccines: current progress. Clin Infect Dis 53: 296-302.
83. Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, et al. (2010) Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 28: 2565-2572.
84. Nochi T, Yuki Y, Takahashi H, Sawada S, Mejima M, et al. (2010) Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater 9: 572-578.
85. Hansen S, Lehr CM, (2012) Nanoparticles for transcutaneous vaccination. Microb Biotechnol 5: 156-167.
86. Liu X, Xu Y, Yu T, Clifford C, Liu Y, et al. (2012) A DNA nanostructure platform for directed assembly of synthetic vaccines. Nano Lett 12: 4254-4259.
87. Tafaghodi M, Saluja V, Kersten GF, Kraan H, Slutter B, et al. (2012) Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: impact of formulation on physicochemical and immunological characteristics. Vaccine 30: 5341-5348.
88. Li N, Peng LH, Chen X, Nakagawa S, Gao JQ, (2011) Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers. Vaccine 29: 6179-6190.
89. Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, et al. (2012) Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci U S A 109: 1080-1085.
90. Doroud D, Rafati S, (2012) Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems. Expert Rev Vaccines 11: 69-86.
91. Poland GA, Ovsyannikova IG, Kennedy RB, Haralambieva IH, Jacobson RM, (2011) Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. OMICS 15: 625-636.
92. Haining WN, Wherry EJ, (2010) Integrating genomic signatures for immunologic discovery. Immunity 32: 152-161.
93. De Gregorio E, Rappuoli R, (2012) Vaccines for the future: learning from human immunology. Microb Biotechnol 5: 149-155.
94. Six A, Bellier B, Thomas-Vaslin V, Klatzmann D, (2012) Systems biology in vaccine design. Microb Biotechnol 5: 295-304.
95. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, et al. (2008) Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205: 3119-3131.
96. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, et al. (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10: 116-125.
97. Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, et al. (2011) Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 12: 786-795.
98. Amit I, Garber M, Chevrier N, Leite AP, Donner Y, et al. (2009) Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science 326: 257-263.
99. Lindqvist M, Nookaew I, Brinkenberg I, Samuelson E, Thorn K, et al. (2011) Unraveling molecular signatures of immunostimulatory adjuvants in the female genital tract through systems biology. PLoS One 6: e20448 doi:10.1371/journal.pone.0020448.
100. Rapin N, Lund O, Bernaschi M, Castiglione F, (2010) Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system. PLoS One 5: e9862 doi:10.1371/journal.pone.0009862.
101. Rapin N, Lund O, Castiglione F, (2011) Immune system simulation online. Bioinformatics 27: 2013-2014.
102. Rapin N, Lund O, Castiglione F (2011) C-Immsim 10.1 server. Available: http://www.cbs.dtu.dk/services/C-ImmSim-10.1/. Accessed August 2012.
103. Legrand N, Ploss A, Balling R, Becker PD, Borsotti C, et al. (2009) Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 6: 5-9.
104. Legrand N, Weijer K, Spits H, (2006) Experimental models to study development and function of the human immune system in vivo. J Immunol 176: 2053-2058.
105. Becker PD, Legrand N, van Geelen CM, Noerder M, Huntington ND, et al. (2010) Generation of human antigen-specific monoclonal IgM antibodies using vaccinated "human immune system" mice. PLoS One 5: e13137 doi:10.1371/journal.pone.0013137.
106. Oberg AL, Kennedy RB, Li P, Ovsyannikova IG, Poland GA, (2011) Systems biology approaches to new vaccine development. Curr Opin Immunol 23: 436-443.
107. Andersen-Nissen E, Heit A, McElrath MJ, (2012) Profiling immunity to HIV vaccines with systems biology. Curr Opin HIV AIDS 7: 32-37.
108. Hilleman MR, (2004) Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections. Proc Natl Acad Sci U S A 101 (Suppl 2):: 14560-14566.